What is triple-negative breast cancer?

Area of Science:

• Oncology
• Genetics
• Pathology

Background:

• Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu overexpression.
• TNBC presents distinct clinical and pathological features, often associated with a poorer prognosis and aggressive behavior.
• Chemotherapy remains the primary treatment for TNBC due to the lack of targeted therapies.

Purpose of the Study:

• To review the definitions and characteristics of triple-negative and basal-like breast cancer.
• To discuss current and emerging therapeutic strategies for these breast cancer subtypes.
• To explore the associations of TNBC with BRCA1 mutations, young age, and African-American ethnicity.

Main Methods:

• Literature review of clinical and pathological studies on triple-negative and basal-like breast cancer.
• Analysis of current treatment guidelines and emerging therapeutic approaches.
• Examination of epidemiological data and genetic associations.

Main Results:

• Most triple-negative tumors align with the basal-like molecular subtype, though the terms are not interchangeable.
• TNBC is linked to BRCA1 mutations, younger patients, and African-American women, with underlying reasons requiring further investigation.
• Current treatment relies on chemotherapy, with ongoing research into targeted therapies.

Conclusions:

• Understanding the unique features of TNBC and basal-like breast cancer is crucial for improving patient outcomes.
• Further research into the biological underpinnings of TNBC associations may reveal novel prevention and treatment strategies.
• Evolving therapies offer hope for more targeted and effective management of these aggressive breast cancer subtypes.